Thrombocytopenic Purpura Clinical Trial
Official title:
Initial Lymphocyte Counts Predictive Value in Immune Thrombocytopenic Purpura
- immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by
increased platelet destruction and decreased platelet number (cooper N et al 2006)
- recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial
autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic
forms may represent two distinct immunopathological disorders ( cooper N et al 2006) (
Gern Sheimer T 2009 )
Immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased
platelet destruction and decreased platelet number ( Cooper N et all 2006) platelet surface
membrane proteins become antigenic for unknown reasons, leading to stimulation of the immune
system, auto antibodies production and platelet destruction ( Gasbarrini A et all 2000) It is
associated with the production of auto antibodies directed against platelet glycoprotein
complex 2b/3a and/or 1b/1x , resulting in accelerated destruction of platelets by the
reticular endothelial system via the activity of Fcc receptor bearing phagocytic cells (
Provan & Newland et al 2002) Recent studies have demonstrated that the pathogenesis of ITP
envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that
acute and chronic forms may represent two distinct immunopathological disorders ( Cooper N et
al 2006) ( Gern Sheimer T 2009)
There are many phases of the disease:
1. Newly diagnosed ITP : for all cases at diagnosis.
2. persistent ITP: for patients with ITP between 3 to 12 months.
3. chronic ITP: for patients with ITP lasting more than one year ( blood journal 2009).
- Although lymphocytopenia is a commonly reported feature of many chronic autoimmune
disorders, differential white cell counts at presentation have seldom been
evaluated as predictors for development of chronic ITP ( Deel MD et al 2013) (Ahmed
et al 2010)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00454857 -
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
N/A | |
Completed |
NCT01444417 -
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
|
Phase 3 | |
Completed |
NCT00508820 -
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
|
Phase 3 | |
Completed |
NCT00117143 -
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
|
Phase 1/Phase 2 | |
Completed |
NCT00415532 -
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
|
Phase 3 |